Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $33,123.12 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 20,964 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $33,123.12. Following the completion of the transaction, the insider directly owned 117,717 shares in the company, valued at $185,992.86. This trade represents a 15.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Timothy Edward Lee also recently made the following trade(s):

• On Tuesday, February 17th, Timothy Edward Lee sold 19,663 shares of Invivyd stock. The shares were sold at an average price of $1.54, for a total value of $30,281.02.

Invivyd Trading Down 3.7%

Invivyd stock opened at $1.55 on Friday. Invivyd, Inc. has a 12-month low of $0.46 and a 12-month high of $3.07. The firm has a market capitalization of $361.34 million, a price-to-earnings ratio of -3.30 and a beta of 0.60. The firm has a 50 day moving average of $2.16 and a 200 day moving average of $1.76.

Analysts Set New Price Targets

A number of research analysts recently weighed in on IVVD shares. D. Boral Capital restated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Finally, HC Wainwright boosted their price target on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Invesco Ltd. increased its holdings in shares of Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after purchasing an additional 71,485 shares during the last quarter. AQR Capital Management LLC grew its holdings in Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after buying an additional 391,617 shares in the last quarter. Vanguard Personalized Indexing Management LLC increased its stake in Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after acquiring an additional 28,146 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Invivyd during the 2nd quarter worth approximately $27,000. Finally, Marshall Wace LLP purchased a new stake in shares of Invivyd during the 2nd quarter worth approximately $158,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.